Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
Year: 2008
Type: article
Abstract: The multitargeted kinase inhibitors (MKIs) sorafenib and sunitinib have shown benefit in patients with renal cell carcinoma, hepatocellular carcinoma (sorafenib), and gastrointestinal stromal tumor (sunitinib). Their efficacy in other malignancies is currently being investigated because of their broad range of activity. The effectiveness of these drugs is somewhat diminished by the development of a variety of toxicities, most notably hand-foot skin reaction (HFSR). Although HFSR does not appear to directly affect survival, it can impact quality of life and lead to MKI dose modification or interruption, potentially limiting the antitumor effect. Currently, no standard guidelines exist for the prevention and management of MKI-associated HFSR. To address this issue, an international, interdisciplinary panel of experts gathered in January 2008 to discuss and evaluate the best-practice management of these reactions. Based on these proceedings, recommendations for the management of HFSR have been provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with MKI therapy.
Source: The Oncologist
Institutions: Northwestern University, Stony Brook Medicine, Stony Brook University, Institut Gustave Roussy, Beth Israel Deaconess Medical Center, National Institutes of Health, National Cancer Institute, University of Tübingen, Christian-Albrechts-Universität zu Kiel, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Georgetown University, Pennsylvania State University, Penn State Milton S. Hershey Medical Center, Cleveland Clinic, New York Medical College, Lady of Mercy Medical Center
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2100512801